Literature DB >> 20464324

Rhabdomyosarcoma of the head and neck: a clinicopathological and immunohistochemical analysis of 29 cases.

Cléverton Roberto de Andrade1, Ademar Takahama Junior, Inês Nobuko Nishimoto, Luiz Paulo Kowalski, Márcio Ajudarte Lopes.   

Abstract

Rhabdomyosarcoma is a malignant tumor occurring more frequently in the childhood. The purpose of this study was to analyze the clinicopathological and immunohistochemical features of rhabdomyosarcomas of the head and neck (RHNs). Twenty nine patients treated in a single institution were selected. The histological slides were reviewed and the tumors were classified. The immunohistochemical reactions were performed using antibodies against vimentin, desmin, myogenin, MyoD1, AE1/AE3, p53, PCNA, Ki67, C-erbB2, FAS and CDK4. The mean age was 14.3 years. The nonparameningeal site was affected in 16 cases (55.2%). Eleven cases (37.9%) affected parameningeal sites and 2 cases the orbit. The p53 was positive in 4 cases (13.8%), CDK4 in 10 cases (34.5%), C-erbB2 in 19 cases (70.4%), FAS in 9 cases (31%), PCNA in 28 cases (96.5%) and Ki67 in 16 cases (55.2%). The overall survival was 28.7% in 5 and 10 years, and p53 expression may be related with poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20464324     DOI: 10.1590/s0103-64402010000100011

Source DB:  PubMed          Journal:  Braz Dent J        ISSN: 0103-6440


  10 in total

1.  Orbital rhabdomyosarcomas: A review.

Authors:  Lama Jurdy; Johanus H M Merks; Bradly R Pieters; Maarten P Mourits; Roel J H M Kloos; Simone D Strackee; Peerooz Saeed
Journal:  Saudi J Ophthalmol       Date:  2013-07

2.  Aggressive fibromatosis of the mandible in a two-month old infant.

Authors:  Achamangalam Nandakumar Arya; Balasubramaniam Saravanan; Krishnamurthi Subalakshmi; Rajendiran Appadurai; Irulandy Ponniah
Journal:  J Maxillofac Oral Surg       Date:  2012-11-30

3.  Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients.

Authors:  Henri Wichmann; Antje Güttler; Matthias Bache; Helge Taubert; Martina Vetter; Peter Würl; Hans J Holzhausen; Alexander W Eckert; Matthias Kappler; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

Review 4.  Head and neck rhabdomyosarcoma: follow-up results of four cases and review of the literature.

Authors:  Dong-Ni Zhou; Qing-Qing Yang; Zhong-Lin Li; Zhi-Yong Pan; Yan-Fei Deng
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 5.  Epididymis rhabdomyoma: a case report and literature review.

Authors:  Yang Han; Xue-shan Qiu; Qing-chang Li; Yu-chen Han; Xu-yong Lin; Qing-fu Zhang; Jian Wang; En-hua Wang; Ze-liang Li
Journal:  Diagn Pathol       Date:  2012-04-20       Impact factor: 2.644

6.  Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Authors:  Lisa E S Crose; Corinne M Linardic
Journal:  Sarcoma       Date:  2011-01-02

7.  Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.

Authors:  Jinxuan Hou; Jixin Dong; Lijun Sun; Liying Geng; Jing Wang; Jialin Zheng; Yan Li; Julia Bridge; Steven H Hinrichs; Shi-Jian Ding
Journal:  J Transl Med       Date:  2011-05-16       Impact factor: 5.531

8.  Alveolar rhabdomyosarcoma of maxilla.

Authors:  Anuradha Ananthaneni; Puneeth Horatti Kuberappa; G Vijay Srinivas; Mohammad Asif Kiresur
Journal:  J Oral Maxillofac Pathol       Date:  2016 Jan-Apr

9.  Oral Subcutaneous Midline Leiomyomatous Hamartoma Presenting as Congenital Incisive Papilla Overgrowth in a Toddler.

Authors:  Ashish Loomba; Shalini Garg; Abhishek Dhindsa; Harshaminder Kaur; Neetu Jain; Promila Dhindsa
Journal:  Contemp Clin Dent       Date:  2017 Jan-Mar

Review 10.  Clinicopathological analysis of head and neck rhabdomyosarcoma: A series of 10 cases and literature review.

Authors:  F-S-C Pontes; J-I de Oliveira; L-L de Souza; O-P de Almeida; E-R Fregnani; R-S Vilela; W-M Silva; F-P Fonseca; H-A-R Pontes
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2018-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.